Posted by Michael Wonder on 30 Oct 2018
Acer Therapeutics submits NDA for Edsivo for the treatment of vEDS
29 October 2018 - Acer Therapeutics today announced that it has submitted a new drug application to the U.S. FDA for Edsivo for the treatment of vascular Ehlers-Danlos syndrome.
Along with the submission, Acer has requested priority review, which if granted, could result in a six-month review period.
Acer is advancing Edsivo (celiprolol), a new chemical entity, for the treatment of vascular Ehlers-Danlos syndrome based on a randomised controlled clinical study of celiprolol.
